Hu HH, et al. - Whether or not a quantification of antibody against hepatitis B virus (HBV) core protein (anti-HBc) can identify patients with undetectable levels of HBV DNA and hepatitis B surface antigen (HBsAg) seroclearance among those who were HBV e antigen (HBeAg)-seronegative is investigated. Researchers performed a retrospective analysis of a large cohort of patients with chronic HBV infection in Taiwan and identified that levels of anti-HBc <3 log IU/mL were associated with undetectable HBV DNA and HBsAg seroclearance within 10 years. Patients who also have levels of HBsAg <102 IU/mL showed higher odds. HBeAg-seronegative patients with HBsAg seroclearance were identified by combining data on levels of HBsAg, HBV DNA, and anti-HBc with AUROC value of 82%.